[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1723114T3 - Biphenyl-forbindelser der er egnede som muskarinreceptorantagonister - Google Patents

Biphenyl-forbindelser der er egnede som muskarinreceptorantagonister

Info

Publication number
DK1723114T3
DK1723114T3 DK05730087T DK05730087T DK1723114T3 DK 1723114 T3 DK1723114 T3 DK 1723114T3 DK 05730087 T DK05730087 T DK 05730087T DK 05730087 T DK05730087 T DK 05730087T DK 1723114 T3 DK1723114 T3 DK 1723114T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
compounds useful
muscarinic receptor
biphenyl compounds
biphenyl
Prior art date
Application number
DK05730087T
Other languages
English (en)
Inventor
Yu-Hua Ji
Yongqi Mu
Craig Husfeld
Li Li
Mathai Mammen
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of DK1723114T3 publication Critical patent/DK1723114T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05730087T 2004-03-11 2005-03-10 Biphenyl-forbindelser der er egnede som muskarinreceptorantagonister DK1723114T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55244304P 2004-03-11 2004-03-11
PCT/US2005/007988 WO2005087738A1 (en) 2004-03-11 2005-03-10 Biphenyl compounds useful as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
DK1723114T3 true DK1723114T3 (da) 2008-07-28

Family

ID=34963910

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05730087T DK1723114T3 (da) 2004-03-11 2005-03-10 Biphenyl-forbindelser der er egnede som muskarinreceptorantagonister

Country Status (27)

Country Link
US (22) US7288657B2 (da)
EP (2) EP1723114B1 (da)
JP (1) JP4837653B2 (da)
KR (1) KR101174740B1 (da)
CN (1) CN1930125B (da)
AR (2) AR048032A1 (da)
AT (2) ATE395335T1 (da)
AU (1) AU2005222411B2 (da)
BR (1) BRPI0508622B8 (da)
CA (1) CA2557479C (da)
CY (1) CY1109015T1 (da)
DE (2) DE602005021258D1 (da)
DK (1) DK1723114T3 (da)
ES (2) ES2345640T3 (da)
HR (1) HRP20080301T3 (da)
IL (1) IL177359A (da)
MA (1) MA28524B1 (da)
MY (1) MY144482A (da)
NO (1) NO338941B1 (da)
NZ (1) NZ549472A (da)
PL (1) PL1723114T3 (da)
PT (1) PT1723114E (da)
RU (1) RU2366656C2 (da)
SI (1) SI1723114T1 (da)
TW (1) TWI341836B (da)
WO (1) WO2005087738A1 (da)
ZA (1) ZA200607099B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560469B2 (en) * 2004-03-11 2009-07-14 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528408A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US7524962B2 (en) * 2004-03-11 2009-04-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723110A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7265133B2 (en) * 2004-03-11 2007-09-04 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
EP1866284A1 (en) * 2005-03-10 2007-12-19 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7629336B2 (en) 2005-03-10 2009-12-08 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008546695A (ja) * 2005-06-13 2008-12-25 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
HRP20130468T1 (en) 2009-04-23 2013-06-30 Theravance, Inc. Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
AU2010273514B2 (en) * 2009-07-15 2015-01-22 Theravance Biopharma R&D Ip, Llc Crystalline freebase forms of a biphenyl compound
ES2544287T3 (es) 2010-07-13 2015-08-28 Theravance Biopharma R&D Ip, Llc Procedimiento de preparación de ácido bifenil 2-ilcarbámico
AU2012212269B2 (en) * 2011-01-31 2016-05-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9679336B2 (en) * 2011-10-19 2017-06-13 Facebook, Inc. Social ad hoc networking protocol and presentation layer
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2016155573A1 (zh) * 2015-03-27 2016-10-06 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
WO2017054702A1 (zh) * 2015-09-28 2017-04-06 四川海思科制药有限公司 一种联苯衍生物及其制备方法和在医药上的用途
CN107849008B (zh) * 2015-10-13 2021-04-09 四川海思科制药有限公司 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
WO2020181035A1 (en) * 2019-03-06 2020-09-10 Barry university Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
CN110526859B (zh) * 2019-08-07 2021-03-12 山东百诺医药股份有限公司 一种瑞维那新中间体及其制备方法和瑞维那新的制备方法
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023017404A1 (en) * 2021-08-13 2023-02-16 Begum Dr M Sasthaa A device, a compound, for inhalation of an anti-viral agent
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN116496206A (zh) * 2023-04-21 2023-07-28 斯坦德药典标准物质研发(湖北)有限公司 一种雷芬那辛杂质ii及其制备方法
CN116640088A (zh) * 2023-05-29 2023-08-25 新领先(重庆)医药科技有限公司 一种高纯度雷芬那辛的制备方法
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US747952A (en) * 1903-03-02 1903-12-29 Harry Cauley Dillon Ironing-board.
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
SE8603252L (sv) 1985-07-30 1987-01-31 Glaxo Group Ltd Anordning for att tillfora lekemedel till patienter
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
PT613371E (pt) 1991-12-18 2002-07-31 Astrazeneca Ab Nova combinacao de formoterol e budesonido
ES2216800T3 (es) 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
GB9206989D0 (en) 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
RU2126001C1 (ru) * 1995-01-10 1999-02-10 Самдзин Фармасьютикал Ко., Лтд Производные пиперазина и фармацевтическая композиция на их основе
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
EP1547636A1 (en) 1995-04-14 2005-06-29 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
US6255303B1 (en) 1998-03-14 2001-07-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone PDE III/IV inhibitors
CO5021210A1 (es) 1998-04-18 2001-03-27 Glaxo Group Ltd Formulacion farmaceutica en aerosol
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
NZ505329A (en) 1998-06-08 2003-05-30 Theravance Inc Two heteroaryl or aryl containing compounds covalently attached via a linker useful as muscarinic receptor antagonists
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
ATE233084T1 (de) 1999-04-14 2003-03-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
DE19933926A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6510182B1 (en) * 1999-10-25 2003-01-21 Freesystems Pte. Ltd. Wireless infrared digital audio system
ATE299494T1 (de) * 1999-12-07 2005-07-15 Theravance Inc Carbamat-derivate als muscarin-rezeptor antonisten
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
PE20020719A1 (es) 2000-12-22 2002-10-11 Almirall Prodesfarma Ag Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
US6656694B2 (en) * 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2288543T3 (es) 2001-03-08 2008-01-16 Glaxo Group Limited Agonistas de beta-adrenorreceptores.
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
KR100912324B1 (ko) 2001-09-14 2009-08-14 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
AU2003258507A1 (en) 2002-07-30 2004-02-23 Unilever Plc Abrasive hard surface cleaning compositions
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ATE435855T1 (de) 2003-11-21 2009-07-15 Theravance Inc Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) 2004-03-11 2009-04-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723110A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7501442B2 (en) * 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7265133B2 (en) 2004-03-11 2007-09-04 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7560469B2 (en) 2004-03-11 2009-07-14 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528408A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008537931A (ja) 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
US7629336B2 (en) * 2005-03-10 2009-12-08 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1866284A1 (en) 2005-03-10 2007-12-19 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008546695A (ja) 2005-06-13 2008-12-25 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
US20070029346A1 (en) * 2005-08-03 2007-02-08 Fu-Tian Hung Pneumatic greaser
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2007127473A2 (en) * 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
AU2010273514B2 (en) 2009-07-15 2015-01-22 Theravance Biopharma R&D Ip, Llc Crystalline freebase forms of a biphenyl compound
ES2544287T3 (es) 2010-07-13 2015-08-28 Theravance Biopharma R&D Ip, Llc Procedimiento de preparación de ácido bifenil 2-ilcarbámico

Also Published As

Publication number Publication date
US20050203133A1 (en) 2005-09-15
IL177359A0 (en) 2006-12-10
US20190047957A1 (en) 2019-02-14
US8912334B2 (en) 2014-12-16
ES2306125T3 (es) 2008-11-01
DE602005006757D1 (de) 2008-06-26
US10570092B2 (en) 2020-02-25
US7521041B2 (en) 2009-04-21
AR048032A1 (es) 2006-03-22
AU2005222411B2 (en) 2011-04-21
US11247969B2 (en) 2022-02-15
US8557997B2 (en) 2013-10-15
US7288657B2 (en) 2007-10-30
NO20064579L (no) 2006-11-08
HK1119672A1 (en) 2009-03-13
ATE395335T1 (de) 2008-05-15
US9926272B2 (en) 2018-03-27
CA2557479C (en) 2013-05-07
BRPI0508622B1 (pt) 2018-05-22
US7550595B2 (en) 2009-06-23
SI1723114T1 (sl) 2008-08-31
EP1723114B1 (en) 2008-05-14
ZA200607099B (en) 2008-09-25
US20110319625A1 (en) 2011-12-29
RU2006135927A (ru) 2008-04-20
US9452161B2 (en) 2016-09-27
TWI341836B (en) 2011-05-11
US20180179161A1 (en) 2018-06-28
BRPI0508622A (pt) 2007-07-31
US20220306579A1 (en) 2022-09-29
KR101174740B1 (ko) 2012-08-17
US10343995B2 (en) 2019-07-09
US20160220551A1 (en) 2016-08-04
US20100249421A1 (en) 2010-09-30
HRP20080301T3 (en) 2008-09-30
DE602005021258D1 (de) 2010-06-24
US20080071088A1 (en) 2008-03-20
US8017783B2 (en) 2011-09-13
US20080095708A1 (en) 2008-04-24
EP1930323B1 (en) 2010-05-12
IL177359A (en) 2012-04-30
NZ549472A (en) 2010-06-25
JP2008532922A (ja) 2008-08-21
CN1930125B (zh) 2010-07-21
US7910608B2 (en) 2011-03-22
US20170204061A1 (en) 2017-07-20
JP4837653B2 (ja) 2011-12-14
AR104444A2 (es) 2017-07-19
KR20070011370A (ko) 2007-01-24
US8173815B2 (en) 2012-05-08
US8273894B2 (en) 2012-09-25
CA2557479A1 (en) 2005-09-22
US12258316B2 (en) 2025-03-25
US20070292357A1 (en) 2007-12-20
US10106503B2 (en) 2018-10-23
US20090226379A1 (en) 2009-09-10
HK1097537A1 (en) 2007-06-29
US8034946B2 (en) 2011-10-11
US20190359570A1 (en) 2019-11-28
US7585879B2 (en) 2009-09-08
CN1930125A (zh) 2007-03-14
MA28524B1 (fr) 2007-04-03
CY1109015T1 (el) 2014-07-02
AU2005222411A1 (en) 2005-09-22
NO338941B1 (no) 2016-10-31
BRPI0508622B8 (pt) 2021-05-25
US20090018165A1 (en) 2009-01-15
US20070265305A1 (en) 2007-11-15
US9283183B2 (en) 2016-03-15
US20140171397A1 (en) 2014-06-19
US20150164795A1 (en) 2015-06-18
US20130172301A1 (en) 2013-07-04
TW200538438A (en) 2005-12-01
US20070292356A1 (en) 2007-12-20
US20120190657A1 (en) 2012-07-26
RU2366656C2 (ru) 2009-09-10
MY144482A (en) 2011-09-30
EP1930323A1 (en) 2008-06-11
EP1723114A1 (en) 2006-11-22
ATE467617T1 (de) 2010-05-15
PL1723114T3 (pl) 2008-10-31
US20200290966A1 (en) 2020-09-17
US20110130422A1 (en) 2011-06-02
PT1723114E (pt) 2008-07-17
US7803812B2 (en) 2010-09-28
US7491736B2 (en) 2009-02-17
WO2005087738A1 (en) 2005-09-22
US8053448B2 (en) 2011-11-08
ES2345640T3 (es) 2010-09-28

Similar Documents

Publication Publication Date Title
DK1723114T3 (da) Biphenyl-forbindelser der er egnede som muskarinreceptorantagonister
LTPA2017005I1 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
DK1740177T3 (da) Antagonister til muskarinfølsomme acetylcholinreceptorer
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK1668014T3 (da) Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DK1928821T3 (da) Carboxamidderivater som muscarinreceptorantagonister
EP1959959A4 (en) MORPHOLIN-CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
EP2079467A4 (en) ANTIDIABETIC BICYCLIC COMPOUNDS
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
DK1951660T3 (da) Histamin-3-receptorantagonister
NL1028624A1 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
DK1943242T3 (da) Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer
DK2374797T3 (da) Benzazepinderivater til anvendelse som vasopressinantagonister
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
DK1912976T3 (da) Indol-3-YL-carbonyl-piperidin-benzoimidazolderivater som V1A-receptorantagonister
IL190900A0 (en) Tricyclic compounds useful as oxytocin receptor agonists
ATE406366T1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
GB0516603D0 (en) Processes for the preparation of organic compounds useful as serotonin receptor antagonists